By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) 

25 Science Park, Room 561

New Haven  Connecticut  06511  U.S.A.
Phone: 203-624-5606 Fax: 203-624-5627


SEARCH JOBS



Segment
Drug Discovery





Company News
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Bolsters Board Of Directors With Appointment Of Christopher Kiritsy 8/15/2014 7:45:00 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Reports Top-Line Results Showing Equivalent Exposures After Oral and Intravenous Delafloxacin Administration 8/11/2014 10:55:15 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Announces Accepted Abstracts At The 2014 Interscience Conference On Antimicrobial Agents And Chemotherapy (ICAAC) 7/24/2014 10:03:57 AM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Phase 3 Study Of I.V. And Oral Delafloxacin Has Begun Enrolling Patients With Acute Bacterial Skin And Skin Structure Infections 5/5/2014 12:27:16 PM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) To Present At Needham & Company's Annual Healthcare Conference 4/3/2014 1:56:25 PM
Melinta Therapeutics (Formerly known as Rib-X Pharmaceuticals, Inc.) Scores $70 Million To Fund Lead Drug Trial 2/10/2014 7:14:58 AM
Rib-X Pharmaceuticals, Inc. Presents Data Demonstrating Potent In Vitro Activity of Delafloxacin Against Drug-Resistant Gonorrhea 7/16/2013 10:13:00 AM
Rib-X Pharmaceuticals, Inc. Initiates Delafloxacin Global Phase 3 Clinical Trial in Patients With Acute Bacterial Skin and Skin Structure Infections 5/14/2013 9:58:00 AM
Rib-X Pharmaceuticals, Inc. Appoints John E. Sununu to the Board of Directors 5/13/2013 7:18:26 AM
Rib-X Pharmaceuticals, Inc. Announces New Executive Leadership and Board of Directors Appointments 4/3/2013 10:50:41 AM
12345678
//-->